PMID- 24141084
OWN - NLM
STAT- MEDLINE
DCOM- 20140210
LR  - 20220310
IS  - 1872-7972 (Electronic)
IS  - 0304-3940 (Linking)
VI  - 556
DP  - 2013 Nov 27
TI  - Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix 
      metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with 
      clozapine.
PG  - 37-41
LID - S0304-3940(13)00883-5 [pii]
LID - 10.1016/j.neulet.2013.09.059 [doi]
AB  - Brain-derived neurotrophic factor (BDNF) regulates the survival and growth of 
      neurons, and influences synaptic efficiency and plasticity. Peripheral BDNF 
      levels in patients with schizophrenia have been widely reported in the 
      literature. However, it is still controversial whether peripheral levels of BDNF 
      are altered in patients with schizophrenia. The peripheral BDNF levels previously 
      reported in patients with schizophrenia were total BDNF (proBDNF and mature BDNF) 
      as it was unable to specifically measure mature BDNF due to limited BDNF antibody 
      specificity. In this study, we examined whether peripheral levels of mature BDNF 
      were altered in patients with treatment-resistant schizophrenia. Matrix 
      metalloproteinase-9 (MMP-9) levels were also measured, as MMP-9 plays a role in 
      the conversion of proBDNF to mature BDNF. Twenty-two patients with 
      treatment-resistant schizophrenia treated with clozapine and 22 age- and 
      sex-matched healthy controls were enrolled. The plasma levels of mature BDNF and 
      MMP-9 were measured using ELISA kits. No significant difference was observed for 
      mature BDNF however, MMP-9 was significantly increased in patients with 
      schizophrenia. The significant correlation was observed between mature BDNF and 
      MMP-9 plasma levels. Neither mature BDNF nor MMP-9 plasma levels were associated 
      clinical variables. Our results do not support the view that peripheral BDNF 
      levels are associated with schizophrenia. MMP-9 may play a role in the 
      pathophysiology of schizophrenia and serve as a biomarker for schizophrenia.
CI  - Copyright (c) 2013 The Authors. Published by Elsevier Ireland Ltd.. All rights 
      reserved.
FAU - Yamamori, Hidenaga
AU  - Yamamori H
AD  - Department of Molecular Neuropsychiatry, Osaka University Graduate School of 
      Medicine, Suita, Osaka 5650871, Japan; Department of Psychiatry, Osaka University 
      Graduate School of Medicine, Suita, Osaka 5650871, Japan.
FAU - Hashimoto, Ryota
AU  - Hashimoto R
FAU - Ishima, Tamaki
AU  - Ishima T
FAU - Kishi, Fukuko
AU  - Kishi F
FAU - Yasuda, Yuka
AU  - Yasuda Y
FAU - Ohi, Kazutaka
AU  - Ohi K
FAU - Fujimoto, Michiko
AU  - Fujimoto M
FAU - Umeda-Yano, Satomi
AU  - Umeda-Yano S
FAU - Ito, Akira
AU  - Ito A
FAU - Hashimoto, Kenji
AU  - Hashimoto K
FAU - Takeda, Masatoshi
AU  - Takeda M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131018
PL  - Ireland
TA  - Neurosci Lett
JT  - Neuroscience letters
JID - 7600130
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Protein Precursors)
RN  - 0 (brain-derived neurotrophic factor precursor)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
RN  - J60AR2IKIC (Clozapine)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/*therapeutic use
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Case-Control Studies
MH  - Clozapine/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 9/*blood
MH  - Middle Aged
MH  - Protein Precursors/*blood
MH  - Schizophrenia/blood/*drug therapy
MH  - Treatment Failure
OTO - NOTNLM
OT  - BDNF
OT  - Brain-derived neurotrophic factor (BDNF)
OT  - Clozapine
OT  - DSM-IV
OT  - MDD
OT  - MMP-9
OT  - Matrix metalloproteinase-9 (MMP-9)
OT  - PANSS
OT  - Treatment-resistant schizophrenia
OT  - brain-derived neurotrophic factor
OT  - diagnostic and statistical manual of mental disorders, fourth edition
OT  - major depressive disorder
OT  - matrix metalloproteinase-9
OT  - positive and negative syndrome scale
EDAT- 2013/10/22 06:00
MHDA- 2014/02/11 06:00
CRDT- 2013/10/22 06:00
PHST- 2013/08/12 00:00 [received]
PHST- 2013/09/09 00:00 [revised]
PHST- 2013/09/25 00:00 [accepted]
PHST- 2013/10/22 06:00 [entrez]
PHST- 2013/10/22 06:00 [pubmed]
PHST- 2014/02/11 06:00 [medline]
AID - S0304-3940(13)00883-5 [pii]
AID - 10.1016/j.neulet.2013.09.059 [doi]
PST - ppublish
SO  - Neurosci Lett. 2013 Nov 27;556:37-41. doi: 10.1016/j.neulet.2013.09.059. Epub 
      2013 Oct 18.